Buscar
Immutep Ltd
IMMPAñadir a la lista de seguimiento
0.520USD
+0.068+15.13%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
63.21MCap. mercado
PérdidaP/E TTM
Más Datos de Immutep Ltd Compañía
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Información de Immutep Ltd
Símbolo de cotizaciónIMMP
Nombre de la empresaImmutep Ltd
Fecha de salida a bolsaJun 23, 1988
Director ejecutivoVoigt (Marc)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 23
DirecciónLevel 32, Suite 32.07 Australia Square
CiudadSYDNEY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal2000
Teléfono61283157003
Sitio Webhttps://www.immutep.com/
Símbolo de cotizaciónIMMP
Fecha de salida a bolsaJun 23, 1988
Director ejecutivoVoigt (Marc)
Ejecutivos de Immutep Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. Frederic Triebel, M.D., Ph.D.
Prof. Frederic Triebel, M.D., Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
17.06K
--
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
45.00
--
Ms. Deanne Miller
Ms. Deanne Miller
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
--
--
Dr. Russell John Howard, Ph.D.
Dr. Russell John Howard, Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Peter A. (Pete) Meyers
Mr. Peter A. (Pete) Meyers
Independent Non-Executive Deputy Chairman of the Board
Independent Non-Executive Deputy Chairman of the Board
--
--
Ms. Indira Naidu
Ms. Indira Naidu
Company Secretary
Company Secretary
--
--
Ms. Lis (Elisabeth) Boyce
Ms. Lis (Elisabeth) Boyce
Non-Executive Director
Non-Executive Director
--
--
Dr. Stephan Winckels
Dr. Stephan Winckels
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Christian Mueller
Mr. Christian Mueller
Chief Development Officer
Chief Development Officer
--
--
Ms. Eleanor Pearson
Ms. Eleanor Pearson
Investors Relation
Investors Relation
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. Frederic Triebel, M.D., Ph.D.
Prof. Frederic Triebel, M.D., Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
17.06K
--
Mr. Marc Voigt
Mr. Marc Voigt
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
45.00
--
Ms. Deanne Miller
Ms. Deanne Miller
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
--
--
Dr. Russell John Howard, Ph.D.
Dr. Russell John Howard, Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Peter A. (Pete) Meyers
Mr. Peter A. (Pete) Meyers
Independent Non-Executive Deputy Chairman of the Board
Independent Non-Executive Deputy Chairman of the Board
--
--
Ms. Indira Naidu
Ms. Indira Naidu
Company Secretary
Company Secretary
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 9 de may
Actualizado: sáb., 9 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Pengana Capital Group Limited
0.66%
BlackRock Institutional Trust Company, N.A.
0.56%
UBS Financial Services, Inc.
0.51%
Meridian Wealth Management, LLC
0.30%
Millennium Management LLC
0.07%
Otro
97.90%
Accionistas
Accionistas
Proporción
Pengana Capital Group Limited
0.66%
BlackRock Institutional Trust Company, N.A.
0.56%
UBS Financial Services, Inc.
0.51%
Meridian Wealth Management, LLC
0.30%
Millennium Management LLC
0.07%
Otro
97.90%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
1.48%
Investment Advisor/Hedge Fund
0.73%
Hedge Fund
0.18%
Research Firm
0.06%
Individual Investor
0.01%
Otro
97.54%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
59
3.75M
2.54%
-339.41K
2025Q4
56
3.29M
2.23%
-370.52K
2025Q3
54
2.86M
1.94%
-666.36K
2025Q2
57
2.80M
1.91%
-1.07M
2025Q1
57
2.80M
1.92%
-1.15M
2024Q4
60
6.95M
4.78%
-4.23M
2024Q3
60
9.14M
6.30%
-2.51M
2024Q2
63
9.65M
6.65%
+2.67M
2024Q1
67
3.50M
2.94%
-1.44M
2023Q4
66
3.16M
2.65%
-1.77M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Pengana Capital Group Limited
970.61K
0.66%
--
--
Aug 31, 2025
BlackRock Institutional Trust Company, N.A.
823.54K
0.56%
+243.10K
+41.88%
Dec 31, 2025
UBS Financial Services, Inc.
70.42K
0.05%
+45.32K
+180.62%
Dec 31, 2025
Meridian Wealth Management, LLC
454.40K
0.31%
+33.50K
+7.96%
Dec 31, 2025
Millennium Management LLC
106.75K
0.07%
+57.45K
+116.55%
Dec 31, 2025
Two Sigma Investments, LP
94.59K
0.06%
+94.59K
--
Dec 31, 2025
Susquehanna International Group, LLP
73.92K
0.05%
-21.34K
-22.40%
Dec 31, 2025
Verition Fund Management LLC
60.00K
0.04%
-15.00K
-20.00%
Dec 31, 2025
LPL Financial LLC
33.98K
0.02%
--
--
Dec 31, 2025
Hilton Capital Management, LLC
30.68K
0.02%
--
--
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Biotechnology ETF
0.02%
ActivePassive International Equity ETF
0%
DFA Dimensional International Small Cap ETF
0%
iShares Biotechnology ETF
Proporción0.02%
ActivePassive International Equity ETF
Proporción0%
DFA Dimensional International Small Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
